ValuEngine cut shares of Irhythm Technologies (NASDAQ:IRTC) from a buy rating to a hold rating in a research report released on Thursday, ValuEngine reports.

Other analysts have also issued reports about the stock. Oppenheimer initiated coverage on shares of Irhythm Technologies in a research note on Tuesday, October 22nd. They set a market perform rating for the company. Zacks Investment Research lowered shares of Irhythm Technologies from a hold rating to a sell rating in a research note on Saturday, November 9th. BidaskClub raised shares of Irhythm Technologies from a strong sell rating to a sell rating in a research note on Friday, October 18th. JPMorgan Chase & Co. boosted their target price on shares of Irhythm Technologies from $110.00 to $125.00 and gave the company an overweight rating in a research note on Thursday, August 1st. Finally, BTIG Research set a $90.00 target price on shares of Irhythm Technologies and gave the company a buy rating in a research note on Wednesday, July 31st. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $99.56.

NASDAQ IRTC traded up $0.31 on Thursday, hitting $69.99. 274,800 shares of the stock were exchanged, compared to its average volume of 387,408. The company has a debt-to-equity ratio of 2.53, a quick ratio of 2.59 and a current ratio of 2.66. The stock has a fifty day moving average price of $68.26 and a two-hundred day moving average price of $73.92. The firm has a market capitalization of $1.63 billion, a P/E ratio of -37.03 and a beta of 1.72. Irhythm Technologies has a 52-week low of $56.24 and a 52-week high of $98.13.

Irhythm Technologies (NASDAQ:IRTC) last issued its earnings results on Tuesday, November 5th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.34). The company had revenue of $55.96 million for the quarter, compared to analysts’ expectations of $53.76 million. Irhythm Technologies had a negative net margin of 26.45% and a negative return on equity of 97.79%. The firm’s revenue for the quarter was up 46.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.43) earnings per share. Sell-side analysts expect that Irhythm Technologies will post -1.96 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Cerebellum GP LLC bought a new stake in shares of Irhythm Technologies in the second quarter valued at about $348,000. Fiera Capital Corp bought a new stake in shares of Irhythm Technologies in the second quarter valued at about $23,766,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Irhythm Technologies by 93.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,825 shares of the company’s stock valued at $144,000 after acquiring an additional 882 shares in the last quarter. NumerixS Investment Technologies Inc bought a new stake in shares of Irhythm Technologies in the second quarter valued at about $477,000. Finally, TimesSquare Capital Management LLC raised its holdings in shares of Irhythm Technologies by 18.2% in the third quarter. TimesSquare Capital Management LLC now owns 698,325 shares of the company’s stock valued at $51,753,000 after acquiring an additional 107,500 shares in the last quarter.

Irhythm Technologies Company Profile

iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.

Featured Story: Using other technical indicators with support levels

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Irhythm Technologies (NASDAQ:IRTC)

Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.